GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Efavirenz (Sustiva)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons

Sustiva / Efavirenz

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Sustiva - product and source limitations

This single-ingredient finding does not establish dosing for combination tablets or dialysis.

Before applying: Verify the current prescribing information for this presentation.

Also check: Sustiva - product and source limitations

Historical source

Original GlobalRPh source

Choose a product and source Sustiva | Product label Sustiva | GlobalRPh RX passage All evidence
Product / population
Preserved GlobalRPh source, not a freshly verified product label
Renal measure
Use the method specified in the original source
Source revision
Historical source; revision not established here
Retrieved
2026-09-05 (not the revision date)

Historical source: not automatically current. Review current official labeling and separately attributed additions before use.

The interacting-drug recommendations are preserved from the historical page and require comparison with current HIV guidance.

Usual Dosing (Adults)

Adults: SUSTIVA 600 mg orally once daily with a protease inhibitor and/or NRTIs. Take on an empty stomach, preferably at bedtime. Food increases concentrations and may increase adverse reactions; bedtime dosing can improve nervous-system tolerability. Always combine with other antiretrovirals.

With voriconazole: increase voriconazole maintenance to 400 mg every 12 hours and decrease efavirenz to 300 mg daily using capsules (one 200 mg plus two 50 mg, or six 50 mg capsules). Do not break SUSTIVA tablets.

With rifampin in patients >=50 kg, the source recommends increasing efavirenz to 800 mg daily.

Renal Dosing

No adjustments needed.

Hemodialysis

Insufficient data.

Source revision: Historical source; revision not established here | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://globalrph.com/renal/efavirenz/

Scope: Preserved historical source; no fresh clinical approval GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Sustiva - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 2, posted Mar 01, 2013

Renal measure: Renal impairment categories as defined by the cited product label

Read this dated source finding
Rxlist

Sustiva - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Sustiva - labeled renal guidance

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Efavirenz (Sustiva), oral tablet

Renal method: Renal impairment categories as defined by the cited product label
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Sustiva - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Sustiva - product and source limitations

This single-ingredient finding does not establish dosing for combination tablets or dialysis.

How to use this: Verify the current prescribing information for this presentation.

Sustiva - labeled renal guidanceSustiva - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeSustiva - labeled renal guidanceSustiva - selected RX renal passageNIH adult ARV table: Efavirenz
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The interacting-drug recommendations are preserved from the historical page and require comparison with current HIV guidance.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/efavirenz/

Usual Dosing (Adults)

Adults: SUSTIVA 600 mg orally once daily with a protease inhibitor and/or NRTIs. Take on an empty stomach, preferably at bedtime. Food increases concentrations and may increase adverse reactions; bedtime dosing can improve nervous-system tolerability. Always combine with other antiretrovirals.

With voriconazole: increase voriconazole maintenance to 400 mg every 12 hours and decrease efavirenz to 300 mg daily using capsules (one 200 mg plus two 50 mg, or six 50 mg capsules). Do not break SUSTIVA tablets.

With rifampin in patients >=50 kg, the source recommends increasing efavirenz to 800 mg daily.

GRPH-efavirenz-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

No adjustments needed.

GRPH-efavirenz-02 · Source section: Renal DosingRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Sustiva - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Efavirenz (Sustiva), oral tablet

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 2, posted Mar 01, 2013
Retrieved: 2026-11-07

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Special Populations

Renal pharmacokinetic studies are lacking. The small fraction of efavirenz eliminated unchanged in urine suggests little direct renal effect on elimination. This single-ingredient finding does not establish dosing for combination tablets or dialysis.

RDM74-sustiva-official-1 · Source locator: Renal guidance: Special Populations

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04b5c345-c446-43a4-83f0-509bc287e10b
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 2, posted Mar 01, 2013
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
22c73921dae20b6ae0806e6348dfe1f1634c440a85d0a90425ed42c32ac1e846
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Sustiva - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Efavirenz (Sustiva), oral tablet

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

Renal pharmacokinetic studies are lacking. The small fraction of efavirenz eliminated unchanged in urine suggests little direct renal effect on elimination.

RDM74-sustiva-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/sustiva-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
c145e9906091eca128f1199fe6f92e1403f77c221eca2b27f7db73275be9d502
Separate professional-source layer

University and professional protocols

Professional

NIH adult ARV table: Efavirenz

Open original reference

Open / share this exact local source

NIH ClinicalInfo HIV guidelines · Adults with HIV; product-specific renal recommendations.

Renal method: CrCl (mL/min), usually Cockcroft-Gault.
Source date: Not established
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

NIH dose and renal statement

Adults: 600 mg orally daily, fasting, preferably at bedtime; renal dose modification is not required.

efavirenz:nih-arv-efavirenz-1 · Source locator: Appendix B: Efavirenz row

Source identity and provenance
Source
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-renal-hepatic-insufficiency-full
Retrieved
2026-09-05
Renal-function method
CrCl (mL/min), usually Cockcroft-Gault.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
621555e79c945b07c76709444f24d00fbea134977a115a55f96c581962531034

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/efavirenz/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
efa630de5a018c0f29bf77ad15ec20c5bc4ea5262058439faaf5706cd652064f
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top